Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: HeatherN who wrote (73708)	11/29/1999 10:08:00 PM
From: kha vu	Read Replies (1) \| Respond to of 120523

Gum Tech International Reports Third Quarter 1999 Results PHOENIX, Nov. 10 /PRNewswire/ -- Gum Tech International, Inc. (Nasdaq: GUMM - news) reported consolidated third quarter net sales of $2.3 million, up over 75% compared to the third quarter of 1998. The Company reported a loss from operations of $223,000, the lowest in the past two years. The net loss for common stock after financing costs was $795,000. biz.yahoo.com

To: HeatherN who wrote (73708)	12/10/1999 1:09:00 PM
From: Street Walker	Respond to of 120523

Been off of SI for a while, to answer your questions: As a physician myself, and having followed GUMM/Zicam and the clinicals for almost a year, I know the medical community has stated over and over they are awaiting the next clincals. The second clinicals and their release in a journal should answer the specific questions you have. It is anectotal the number of colds that zicam has eliminated in a little over a day. With a p value of <0.001 in the first clinicals, I'm expecting the second clincils to confirm Zicam reduces the common cold to around 1.5 days on average. Sales figures: They are producing around 80,000 units a day. They are back ordered. The orders from other countries have been put on hold so they can catch up on all the orders here in the US. They are back ordered by several weeks. Net profit per unit is around $1.75 so the math will reveal incredible returns. Technically, the chart is extremely bullish. Maybe the second clincals are VERY SOON to be released. That would be great for share holders. I'm sure the news will get national attention. You may want to wait and buy GUMM after a journal reports the results and pay much higher so that your detailed questions are answered fully. Myself, I think its best to buy before the "VERY SOON" occurs. Regards, S.W.